Compare Ginkgo Bioworks Holdings Inc (DNA) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs CarMax, Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while CarMax, Inc trades at $52.72 (market cap $7.64B). The key difference: CarMax, Inc is far larger — about 10× Ginkgo Bioworks Holdings Inc's market cap, and CarMax, Inc is more actively traded (3,610,116 versus 3,204,177). Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and CarMax, Inc for 49 Days on average.
| DNA | KMX | |
|---|---|---|
Market Cap | $763.64M | $7.64B |
Volume | 3,204,177 | 3,610,116 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $64.22 |
52-Week Low | $5.48 | $30.88 |
Typical Hold Time | 7 Days | 49 Days |
Enterprise Value | $865.59M | $25.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
CarMax (KMX) trades at $52.82, down 0.86% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $1.16 beating estimates by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show a P/E of 25.37 and P/S of 0.28, while profitability remains modest with 1.06% net margin. Recent news highlights the company's 'Shift into GEAR' turnaround strategy showing early success.
KMX presents a mixed outlook with improving operational performance offset by high debt levels and competitive pressures. The consensus price target of $58.89 suggests 11% upside potential, but analysts remain cautious with 62% hold ratings. Key risks include cyclical auto market exposure and interest rate sensitivity, while catalysts include continued execution of the turnaround strategy and potential share buybacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
